(+)-.ALPHA.-Viniferin, a Stilbene Trimer from Caragana chamlague, Inhibits Acetylcholinesterase.

Abstract

Alzheimer's disease (AD) is the most common cause of senile dementia in later life. Whereas several neurotransmitter systems are known to be involved and depleted in AD, the cholinergic system still receives the greatest attention by far. This is particularly true with regards to pharmacotherapy research and development 2) due to the involvement of the cholinergic system in learning and memory processing.

Cholinesterase and microbial inhibitory activities of Tetrapleura tetraptera

“…Apart from the pesticidal activities of the plants studied, their cholinesterase properties could further be used to explore their potential in drug discovering for the treatment of the above mentioned ailments. However, a good number of plant extracts and pure components of natural origin have been reported to have anticholinesterase property (Sung et al, 2002;Ahmed et al, 2003;Ortega et al, 2004;Orhan et al, 2004;Rafeeq et al, 2006;JohnBull and Muluh, 2009). …”

<i>In vitro</i> acetylcholinesterase and butyrylcholinesterase inhibitory potentials of essential oil of <i>Artemisia macrocephala</i>

“…Alzheimer's disease patients show a progressive loss of cholinergic synapses in the brain regions performing higher mental func- acetylcholine through the inhibition of both forms of cholinesterase: AChE and BChE. Moreover, the inhibition of AChE plays a key role not only enhancing cholinergic transmission in the brain, but also reducing the aggregation of amyloid beta peptide (A ) and the formation of the neurotoxic fibrils in Alzheimer's disease (Candy et al, 1983;Sung et al, 2002).…”

In vitro inhibition of acetylcholinesterase by crude plant extracts from Colombian flora

“…AChE inhibitors are the most effective approach to treat the cognitive symptoms of Alzheimer disease (AD) (Kalauni et al 2002) and other possible therapeutic applications in the treatment of Parkinson's disease, senile dementia, and ataxia, among others (Ahmad et al 2003a). AChE inhibitors as eserine, tacrine, donepezil, rivastigmine, and galanthamine are the only drugs currently approved for the treatment of AD; however, these drugs are known to have limitations for clinical use due to their short-half-lives and/or unfavorable side-effects (Sung et al 2002).Because the search of plant extracts that selectively inhibit AChE is of paramount importance to find novel and more potent AChE inhibitors, many of them have been screened and as consequence there have been found extracts and isolated pure compounds with AChE and/or butyrylcholinesterase (BChE) inhibitory properties. Among the plant families that have been examined for their AChE inhibitory activity are: Amaryllidaceae Continuing with the study of the flora from Regional Natural Park Ucumarí (RNPU, Risaralda, Colombia) as a source of new secondary metabolites with diverse grade of biological activities (Niño et al 2003, 2006, Mosquera et al 2004a) and the fact that there still is great interest in finding novel and better AChE inhibitors, prompted us to screen 27 crude methanol extracts belonging to the Asteraceae, Euphorbiaceae, Melastomataceae, Rubiaceae, and Solananceae families for their AChE inhibitory activities.…”

“…AChE inhibitors are the most effective approach to treat the cognitive symptoms of Alzheimer disease (AD) (Kalauni et al 2002) and other possible therapeutic applications in the treatment of Parkinson's disease, senile dementia, and ataxia, among others (Ahmad et al 2003a). AChE inhibitors as eserine, tacrine, donepezil, rivastigmine, and galanthamine are the only drugs currently approved for the treatment of AD; however, these drugs are known to have limitations for clinical use due to their short-half-lives and/or unfavorable side-effects (Sung et al 2002).…”